Pricing Log in Create free account
Saturday 17 October 2026 Export BAX’s income statement to Excel — free account

Baxter International Inc.

BAX Healthcare Medical Instruments & Supplies

Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024. In the quarter to June 2026, revenue grew 5.34%, EPS grew 33.3%, free cash flow grew 119.5% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.

25.33 0.43 −1.67%
Market cap
$13.3B
P/E
0.0×
Fwd P/E
44.7×
Dividend yield
0.16%
F-score
4/9
Altman Z
2.12
Beneish M
−2.67
Dividend safety
0/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Baxter International Inc. (BAX) SEC filings, changes and red flags

Red flags

  • Officer departure

    Baxter International Inc. reported the departure of an officer or director

    8-K filed · The filing · sec.gov

  • Impairment

    Baxter International Inc. recorded a goodwill impairment of $485.0 million in fiscal 2025

    10-K filed · The filing · sec.gov

Filings

Form Period Filed What it reports Flags
8-K Aug 18, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits Officer departure
8-K Aug 18, 2026 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jul 31, 2026 5.02 Departure or appointment of directors or officers
8-K Aug 4, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 11 added · 10 removed · 74 modified
P2I1A: no changes
8-K Jul 29, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jul 14, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 4, 2026 5.02 Departure or appointment of directors or officers; 5.03 Amendments to the articles or bylaws; change in fiscal year; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Apr 29, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Mar 19, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 15, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 2 added · 4 removed · 39 modified
1A: 57 added · 52 removed · 99 modified
7: 73 added · 109 removed · 75 modified 		Impairment
8-K Feb 10, 2026 2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Dec 22, 2025 8.01 Other events
8-K Dec 4, 2025 1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.03 Creation of a direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 25, 2025 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Nov 19, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 19, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Nov 5, 2025 5.02 Departure or appointment of directors or officers
10-Q Sep 30, 2025
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 16, 2025 5.02 Departure or appointment of directors or officers
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.